1. Characterization of Viloxazine Effects on Cortical Serotonin Neurotransmission at Doses Relevant for ADHD Treatment. (April 2023) Authors: Garcia-Olivares, Jennie; Yegla, Brittney; Earnest, Jami; Maletic, Vladimir; Yu, ChungPing Journal: CNS spectrums Issue: Volume 28:Number 2(2023) Page Start: 235 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effects of Viloxazine ER (Qelbree®) on Weight and Height Trajectories: Interim Results From a Long-term, Open-Label Extension Trial in Pediatric ADHD. (April 2023) Authors: Nasser, Azmi; Hull, Joseph; Earnest, Jami; Koch, Jennifer; Liranso, Tesfaye; Maldonado-Cruz, Zulane; Rubin, Jonathan; Childress, Ann Journal: CNS spectrums Issue: Volume 28:Number 2(2023) Page Start: 218 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Evaluating the Impact of Caffeine on the Incidence of Adverse Events During Treatment with Viloxazine Extended-Release (Qelbree®) in Adults with ADHD. (April 2023) Authors: Nasser, Azmi; Gomeni, Roberto; Hull, Joseph; Maldonado-Cruz, Zulane; Earnest, Jami; Rubin, Jonathan Journal: CNS spectrums Issue: Volume 28:Number 2(2023) Page Start: 234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗